GlaxoSmithKline: Cardiovascular Diseases trials
The registry lists 20 Cardiovascular Diseases studies with GlaxoSmithKline as lead sponsor. 2 are open to participants now and 7 have results posted.
Phase 1 5Phase 2 2Phase 3 6Phase 4 1No phase 6(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study on the Impact of Recombinant Zoster Vaccine on Major Adverse Cardiovascular Events in Adults >=50 Years of Age With Established Cardiovascular Disease or With >=2 Cardiovascular Risk FactorsNot yet recruitingNCT07872046Phase 3
- A Study Exploring the Effect of Adjuvanted RZV or RSVPreF3 Vaccines on Coronary Plaque Progression in Adults >=50 Years of Age at Risk for Cardiovascular EventsNot yet recruitingNCT07712380Phase 2
- Evaluation of a New Thermostable Formulation of FLOLAN in Japanese SubjectsCompletedNCT02705807Phase 4Results posted
- A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)CompletedNCT02145468Phase 3Results posted
- Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular DiseaseCompletedNCT01627327Phase 3Results posted
- Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary DiseaseCompletedNCT01313676Phase 3Results posted
- The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 TrialCompletedNCT01000727Phase 3Results posted
- Evaluation of Fondaparinux in Patients With a Heart Rhythm Disturbance Who Undergo Restoration of Normal Heart RhythmCompletedNCT00911300Phase 2Results posted
- The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy TrialCompletedNCT00799903Phase 3Results posted
- Bioequivalence Study of Clopidogrel 75 mg in Two Tablet Formulations Relative to Reference Tablet in Healthy SubjectsCompletedNCT02502812Phase 1
- Relative Bioavailability Study of Candesartan Cilexetil Under Fasting ConditionsCompletedNCT02254447Phase 1
- SB-480848 in Major Adverse Cardiovascular Events - Integrated Summary of Efficacy and Safety From the STABILITY Trial (LPL100601) and the SOLID-TIMI-52 Trial (SB-480848/033)CompletedNCT01636271
- Assessment of Comorbidities in Chronic Obstructive Pulmonary Disease (COPD) in European Symptomatic Subjects From Primary CareCompletedNCT01516528
- Special Drug Use Investigation for ARIXTRA (Fondaparinux) Abdominal General SurgeryCompletedNCT01390896
- Special Drug Use Investigation for ARIXTRA (Fondaparinux) Abdominal (Urology,Obstetrics,Gynecology)CompletedNCT01390883
- Drug Use Investigation for FLOLAN (Epoprostenol) Injection 0.5mg・1.5mgCompletedNCT01387191
- HIV Treatment and CVD EventsCompletedNCT01054638
- PK Study of IV Formulation of GW856553CompletedNCT01039961Phase 1
- An Open-label Single Dose Randomized, Parallel Group Study Followed by Single-blind Repeat Dosing, to Compare the Relative Bioavailability of GSK2212836.CompletedNCT00996268Phase 1
- A Study Investigating Blood Concentrations Of Rosuvastatin When Co-administered With GW856553 In Healthy MenCompletedNCT00549653Phase 1